Concourse Financial Group Securities’s Ionis Pharmaceuticals IONS Stock Holding History

Concourse Financial Group Securities’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-26	Closed	-$1.21K	–	2315
2024 Q2	$1.24K	Buy	26 +7	+37%	+$287	﹤0.01%	2094
2024 Q1	$823	Hold	19	–	–	﹤0.01%	2164
2023 Q4	$961	Hold	19	–	–	﹤0.01%	2117
2023 Q3	$861	Buy	+19	New	+$784	﹤0.01%	2117
2022 Q2	–	Sell	-214	Closed	-$8.07K	–	2243
2022 Q1	$8K	Buy	214 +11	+5%	+$360	﹤0.01%	1751
2021 Q4	$6K	Buy	203 +83	+69%	+$2.61K	﹤0.01%	1999
2021 Q3	$4K	Sell	120 -7	-6%	-$264	﹤0.01%	2123
2021 Q2	$5K	Buy	127 +5	+4%	+$196	﹤0.01%	2047
2021 Q1	$5K	Buy	+122	New	+$6.8K	﹤0.01%	1967
2019 Q2	–	Sell	-95	Closed	-$6.71K	–	2323
2019 Q1	$7K	Hold	95	–	–	﹤0.01%	1635
2018 Q4	$5K	Hold	95	–	–	﹤0.01%	1658
2018 Q3	$5K	Buy	+95	New	+$4.46K	﹤0.01%	1395

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Concourse Financial Group Securities's IONS Position: Q3 2024 in Review

Concourse Financial Group Securities sold out of Ionis Pharmaceuticals (IONS) in Q3 2024, closing a stake of 26 shares — an estimated $1.21K sold.

Concourse Financial Group Securities first reported a position in IONS in Q3 2018 and held it in 12 quarters. The position peaked at $8K in Q1 2022. 354 funds tracked by Wall St. Rank hold IONS as of Q3 2024.

Concourse Financial Group Securities reported no remaining Ionis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Concourse Financial Group Securities sold 26 Ionis Pharmaceuticals shares in Q3 2024, an estimated $1.21K.
Concourse Financial Group Securities first reported a position in Ionis Pharmaceuticals in Q3 2018 and held it in 12 quarters.
Concourse Financial Group Securities's Ionis Pharmaceuticals position peaked at $8K in Q1 2022.
354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2024.

Based on Concourse Financial Group Securities's 13F filing for Q3 2024, filed 10 Oct 2024.